QUANTIFY RESEARCH is a global partner to the pharmaceutical industry in close partnership with academia, patients, public institutions & clinical experts.
Real-world evidence & analytics
Quantify is the leading provider of RWE generated from the world-renouned Nordic data. Through our local presence, expert staff, institutional know-how and more than 10 years’ hands-on experience with the Nordic data, we offer an unparalleled ability to advise and execute Nordic RWE studies with local and global applications. Quantify has a successful track record of advising clients on securing Nordic ethical approval, data access, and optimizing analysis for commercial or regulatory purposes. We also offer RWE services in the EU, UK, and US.
Modelling, Access & Strategy
Quantify is a global provider of health economic evidence and a specialist provider of Nordic market access services including economic models, reimbursement dossiers, and strategic advice. Our experience and expertise ensures an optimized, streamlined market access process across the Nordics. For non-technical stakeholders, Quantify also develops value tools and visualisation dashboards to enhance communication. Our expert staff include ex-payers, ex-pharma, modelling experts, and experienced project managers.
Evidence review & synthesis
Quantify has long standing experience reviewing, interpreting and communicating evidence as part of targeted or systematic literature reviews (SLR). Our team ensures these activities are done systematically, with a focus on usability, to support knowledge management and commercialization activities. QUANTIFY is experienced in summarizing the results of this work through meta-analyses and narrative reviews. Our team consists of 50% PhDs and integrated AI solutions to provide our clients with the very best services.
Press
Study published in Acta Oncologica journal
A description of the use of ALK-TKI treatment for patients with ALK positive advanced non-small cell lung cancer, co-authored by Quantify’s Rosa Lauppe and Mathias Lilja, has been published in the Acta Oncologica journal.
Using Swedish national registry data, this study provides a unique overview of all patients treated with Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors (ALK-TKI) therapies in Sweden and offers […]
Quantify parterns with IFPA on Psoriasis study
Anders Gustavsson in Alzheimer panel
Quantify partner Anders Gustavsson participated in a panel on Alzheimer innovations and capacity challenges within the Swedish health care system. We call for 1) a National Alzheimer plan including a priority framework to identify and treat patients with the greatest potential benefit, 2) investments in health care staff, their competence and novel diagnostic innovations, and 3) a long-term perspective on further research and innovation in this field. The panel starts 31 […]
ISPOR day two
It’s been another great day at #isporeurope! We’ve had a full day discussing many exciting topics with our clients and friends. The team also presented four research posters today. As a bonus, our own Béranger Lueza became the newest face of ISPOR […]